Is Bloodless Transplant Feasible in Multiple Myeloma?
Undergoing bloodless autologous stem cell transplantation could be a viable option for some multiple myeloma patients according to a retrospective study. (Source: CancerNetwork)
Source: CancerNetwork - December 15, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Curative Treatment for SPMs in Myeloma Patients
A new study shows benefits in curative treatment approaches to secondary cancers among patients with myeloma. (Source: CancerNetwork)
Source: CancerNetwork - December 15, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Foundation linked to It Works! donates $3M to Moffitt to help cure rare cancer
Moffitt Cancer Center has received a $3 million gift from a foundation linked to Bradenton-based company It Works! The Pentecost Foundation, created through Mark Pentecost, the CEO of It Works!, a direct sales enterprise that sells body contouring wraps, recently made a $3 million gift to Moffitt Cancer Center to support the research at the forefront of curing his multiple myeloma, a type of blood cancer. Multiple myeloma, also known as Kahler's disease, is a cancer of plasma cells, which are… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 12, 2018 Category: Biotechnology Authors: Veronica Brezina-Smith Source Type: news

Quiz: Multiple Myeloma Patients With AL Amyloidosis
Challenge yourself with our latest quiz covering management of AL amyloidosis in the treatment of patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - December 10, 2018 Category: Cancer & Oncology Source Type: news

Daratumumab Plus Len/Dex: New Standard of Care in Myeloma? Daratumumab Plus Len/Dex: New Standard of Care in Myeloma?
Adding daratumumab to lenalidomide and dexamethasone increased progression-free survival in transplant-ineligible patients newly diagnosed with myeloma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Profiling a killer in warm blood
(Weizmann Institute of Science) Israeli scientists and physicians develop a new technology for profiling the unique genetic makeup of myeloma tumor cells that will allow better diagnosis and treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Does Adding Daratumumab Benefit Transplant-Ineligible Myeloma Patients?
Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients. (Source: CancerNetwork)
Source: CancerNetwork - December 5, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

FDA fast tracks Amgen myeloma treatment
The drugmaker's trial of its bispecific antibody for multiple myeloma found that seven out of ten patients given the second-highest dose of AMG420 responded to the drug (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 4, 2018 Category: Pharmaceuticals Source Type: news

New DARZALEX ® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson's multiple myeloma drug reduces risk of death in late-stage study
Johnson& Johnson's blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Combination Regimen Extends PFS in Myeloma
(MedPage Today) -- Large benefit but relevance of comparator questioned (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 4, 2018 Category: Hematology Source Type: news

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Amgen antibody shows promise in myeloma trial, gets FDA fast track
Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Amgen's AMG420 shows responses in myeloma trial, gets FDA fast track
Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, on Monday said seven out of ten patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE ® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia FDA Grants Fast Track Designation for AMG 420 THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in pat...
Source: Amgen News Release - December 4, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Uncovering Novel Data on Myeloma Patients Treated With Proteasome Inhibitors
Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors. (Source: CancerNetwork)
Source: CancerNetwork - December 4, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Dana-Farber to present research on myeloma progression from precursor conditions
(Dana-Farber Cancer Institute) Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the ASH Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

Single or Double Autologous Transplantation in New Myeloma Cases?
Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results. (Source: CancerNetwork)
Source: CancerNetwork - December 2, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

DARZALEX ® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 1, 2018 Category: Pharmaceuticals Source Type: news

Early Intervention With New Drug Combo Beneficial in Myeloma?
This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Pemphigus Vulgaris as Manifestation of Multiple Myeloma Pemphigus Vulgaris as Manifestation of Multiple Myeloma
This case illustrates an uncommon occurrence of multiple myeloma initially presenting with pemphigus vulgaris.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Is the golden spice a golden cure? Woman, 67, beat blood cancer after stopping traditional treatments and using TURMERIC
(Natural News) A 67-year-old woman from London, England has reportedly put an end to her years-long battle with blood cancer with turmeric. Doctors reportedly claim to have never seen anything like this before, where medicinal plant compounds have actually cured someone’s cancer. Formally known as myeloma, this type of cancer is formed by malignant plasma... (Source: NaturalNews.com)
Source: NaturalNews.com - November 14, 2018 Category: Consumer Health News Source Type: news

Impact of Elotuzumab on Multiple Myeloma Patients
The ELOQUENT-3 trial looks at how the of addition of elotuzumab to pomalidomide and dexamethasone impacts patient outcomes in multiple myeloma.   (Source: CancerNetwork)
Source: CancerNetwork - November 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Race and Efficacy of Monoclonal Antibodies in Multiple Myeloma
Does patient race play a role in the efficacy of monoclonal antibodies in multiple myeloma? (Source: CancerNetwork)
Source: CancerNetwork - November 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Quiz: Imaging and Therapy in Multiple Myeloma
How much do you know about diagnostic imaging's role in multiple myeloma? Take our latest quiz to find out more (Source: CancerNetwork)
Source: CancerNetwork - November 8, 2018 Category: Cancer & Oncology Source Type: news

Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
In phase 2 trial, longer progression - free survival for elotuzumab with pomalidomide and dexamethasone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 8, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
WEDNESDAY, Nov. 7, 2018 -- For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival is longer in those receiving the immunostimulatory monoclonal antibody elotuzumab in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2018 Category: Pharmaceuticals Source Type: news

Blood cancers can be treated safely and naturally with cinnamon
(Natural News) Cinnamon does more than add a pleasant and appetizing aroma to your favorite dishes – it can also help treat certain cancers. A study published in the Journal of Herbal Medicine found that cinnamon has the ability to modify the growth of and kill blood cancer cells. Myeloma is a type of blood... (Source: NaturalNews.com)
Source: NaturalNews.com - November 7, 2018 Category: Consumer Health News Source Type: news

FDA OK's New Triplet Tx for Revlimid-Refractory Multiple Myeloma
(MedPage Today) -- Agent doubled overall response rate, progression-free survival (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 7, 2018 Category: American Health Source Type: news

FDA Approves Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 6, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE® Immunotherapy Platform Across Hematologic Malignancies BLINCYTO® (blinatumomab) Long-Term Data Demonstrate Benefits of Achieving Complete MRD Response in Adult Patients With Acute Lymphoblastic Leukemia and Reinforce BiTE® Proof-of-Concept Data From Multiple Myeloma Research Foundation CoMMpass Trial of KYPROLIS® (carfilzomib) in Newly Diagnosed Multiple Myeloma Patients to be Presented at ASH THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today ann...
Source: Amgen News Release - November 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Genetic Sequencing Uncovers New Options for Multiple Myeloma Patients
A small pilot study suggests the approach can identify effective treatments already approved for other cancers. (Source: The Scientist)
Source: The Scientist - November 1, 2018 Category: Science Tags: Notebook Source Type: news

NUS study: RNA defects linked to multiple myeloma progression in high risk patients
(National University of Singapore) Researchers from the Cancer Institute of Singapore (CSI Singapore) at the National University of Singapore have uncovered an association between RNA abnormalities and MM progression. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2018 Category: International Medicine & Public Health Source Type: news

New drug candidates reverse drug resistance in multiple myeloma in preclinical models
(Medical University of South Carolina) A new strategy to enhance the activity of proteasome inhibitors (PIs), which are standard-of-care agents in the treatment of multiple myeloma (MM), was reported by researchers at the Medical University of South Carolina in the journal Leukemia. Their study introduces a new drug candidate that overcomes PI resistance in cultured cells and extends survival in mouse models of MM (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 29, 2018 Category: Cancer & Oncology Source Type: news

Cinnamon is a potent anti-cancer agent
(Natural News) The anti-inflammatory activity of cinnamon is well-established. Researchers, in a study published in the Journal of Herbal Medicine, confirmed that the spice also has antiproliferative and anti-angiogenic properties against cancer cells, specifically, myeloma tumor cells. The researchers treated RPMI 8226 human myeloma cancer cells with 72 micrograms per milliliter (mcg/mL) of cinnamon bark... (Source: NaturalNews.com)
Source: NaturalNews.com - October 26, 2018 Category: Consumer Health News Source Type: news

Multiple Myeloma Concealed by Adrenal Cushing Syndrome Multiple Myeloma Concealed by Adrenal Cushing Syndrome
This unusual case of Cushing syndrome coexisting with multiple myeloma highlights the difficulty of both diagnosis and treatment of two diseases with overlapping symptoms.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Thalidomide-Based Treatment Too Risky in Multiple Myeloma?
A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients. (Source: CancerNetwork)
Source: CancerNetwork - October 15, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

FDA Approves Once-Weekly Carfilzomib for Myeloma
FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - October 15, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

UAMS Hopes Myeloma Audit Cuts to the Bone
The audit of the Myeloma Institute should be able to determine if there’s any money unaccounted for in the cancer program. The accounting is expected to be final after January. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - October 15, 2018 Category: American Health Source Type: news

Gene types linked to higher myeloma diagnoses among African-Americans
Three specific gene types were associated with two-to-three-fold higher myeloma diagnoses among African-Americans compared with European Americans. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 10, 2018 Category: Consumer Health News Source Type: news

Mayo Clinic researchers identify gene types driving racial disparities in myeloma
(Mayo Clinic) Researchers at Mayo Clinic have identified three specific gene types that account for a known two-to-three-fold increase in myeloma diagnoses among African-Americans. Researchers also demonstrated the ability to study race and racial admixture more accurately using DNA analysis. The findings were published today in Blood Cancer Journal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2018 Category: Cancer & Oncology Source Type: news

Mayo Clinic researchers identify gene types driving racial disparities in myeloma
ROCHESTER Minn. ? Researchers at Mayo Clinic have identified three specific gene types that account for a known two-to-three-fold increase in myeloma diagnoses among African-Americans. Researchers also demonstrated the ability to study race and racial admixture more accurately using DNA analysis. The findings were published today in Blood Cancer Journal. ??Myeloma is a serious blood [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - October 10, 2018 Category: Research Source Type: news

MRD Status May Outweigh Cytogenetic Risk as Prognostic Marker for Myeloma
Minimal residual disease negativity measured by next-generation sequencing was a valuable prognostic biomarker for multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - October 5, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Quiz: Understand Quality of Life Obstacles for Multiple Myeloma Patients
Do you know about the quality of life obstacles for multiple myeloma patients? Take our latest quiz to test your knowledge. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Approval of a More Convenient Once-Weekly Kd70 Regimen Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study Application Granted Priority Review Designation Application Reviewed and Approved Under FDA's Real-Time Oncology Review and Assessment Aid... Biopharmaceuticals, Oncology, FDA Amgen, KYPROLIS, carfilzomib, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 1, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves KYPROLIS ® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Approval of a More Convenient Once-Weekly Kd70 Regimen Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study Application Granted Priority Review Designation Application Reviewed and Approved Under FDA's Real-Time Oncology Review and Assessment Aid Pilot Programs THOUSAND OAKS, Calif., Oct. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly...
Source: Amgen News Release - October 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Kyprolis (carfilzomib) Once-Weekly Kd70 Regimen for Relapsed or Refractory Multiple Myeloma
THOUSAND OAKS, Calif., Oct. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for Kyprolis... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 1, 2018 Category: Drugs & Pharmacology Source Type: news

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma
(Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2018 Category: American Health Source Type: news

Low-cost, chip-based blood test for multiple myeloma may be safer and less painful alternative to bone biopsy
(Natural News) As if the pain of having and living through cancer wasn’t bad enough, diagnosing the disease is, in itself, an ordeal. But invasive biopsies may soon be a thing of the past, thanks to a low-cost, chip-based blood test developed by researchers at the University of Kansas (KU), according to a study published... (Source: NaturalNews.com)
Source: NaturalNews.com - September 22, 2018 Category: Consumer Health News Source Type: news

Radiological Case: Multiple Myeloma Radiological Case: Multiple Myeloma
This 93-year-old male initially presented with clinical findings and history most suggestive of genitourinary pathology. How was the eventual diagnosis of multiple myeloma made?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2018 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news